Paolo Bossi, Head of the Head and Neck Medical Oncology Unit and Associate Professor of Medical Oncology at Humanitas University and Humanitas Cancer Center, shared a post on LinkedIn about a paper he co-authored with colleagues published in the European Journal of Cancer:

“Immunotherapy followed by cetuximab in locally advanced/metastatic cutaneous squamous cell carcinomas: the I-TACKLE trial”

Authors: Paolo Bossi, Andrea Alberti, Cristiana Bergamini, Carlo Resteghini, Laura Deborah Locati, Luigi Lorini, Alberto Grammatica, Roberto Patuzzo, Andrea Maurichi, Lisa Francesca Licitra et al.

Paolo Bossi: Immunotherapy plus cetuximab in advanced/metastatic cutaneous squamous cell carcinoma

“I Tackle: second line with cetuximab and pembrolizumab in cutaneous squamous cell carcinoma.

Highlights:

First study on PD-1 blockade + EGFR inhibition in recurrent/metastatic cSCC.
Cetuximab overcame pembrolizumab resistance, reaching a 63 % cumulative ORR.
Cetuximab reversed primary/acquired resistance in 43 % of cSCC cases, with safety.”

Luigi Lorini, Medical Oncologist at Humanitas Research Hospital, shared this post, adding:

“What about an EGFR inhibitor to reverse ICIs resistance in cutaneous squamous cell carcinoma?

Reach out our latest publication on this topic!”

More posts featuring Paolo Bossi and Luigi Lorini.